{{Rsnum
|rsid=17169056
|Chromosome=7
|position=15751201
|Orientation=plus
|GMAF=0.08173
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 60.6 | 31.4 | 8.0
| JPT | 73.5 | 22.1 | 4.4
| YRI | 84.4 | 15.6 | 0.0
| ASW | 89.5 | 10.5 | 0.0
| CHB | 60.6 | 31.4 | 8.0
| CHD | 54.7 | 40.6 | 4.7
| GIH | 93.9 | 6.1 | 0.0
| LWK | 79.4 | 19.6 | 0.9
| MEX | 98.3 | 1.7 | 0.0
| MKK | 83.2 | 16.8 | 0.0
| TSI | 99.0 | 1.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17169056
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.02, combined P value= 1.45E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470162
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17169056
|overall_frequency_n=6
|overall_frequency_d=128
|overall_frequency=0.046875
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}